|Articles|October 1, 2019

Headspace platforms and services for CCI testing, oxygen monitoring, and water activity determination

LIGHTHOUSE offers solutions for Container Closure Integrity Testing, headspace Oxygen Monitoring, Moisture Determination of dry product, and Microbial Contamination inspection of media vials.

 

LIGHTHOUSE offers solutions for Container Closure Integrity Testing, headspace Oxygen Monitoring, Moisture Determination of dry product, and Microbial Contamination inspection of media vials. Our solutions are based on rapid non-destructive laser-based headspace analysis, a proven analytical tool for generating statistical process and product data in all stages of the product life cycle. The LIGHTHOUSE offering includes headspace analysis equipment as well as measurement services. The range of application solution activities can cover feasibility studies, analytical process and product studies, method development, method validation protocols, supply of automated or benchtop platforms, and on-site troubleshooting and support.

 

Contact Details

Company name: LIGHTHOUSE Instruments

Website: www.lighthouseinstruments.com

E-mail: euinfo@lighthouseinstruments.com

Stand/Booth number: Hall 11, Stand 110C35


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.